Sirolimus stimulates vascular stem/progenitor cell migration and differentiation into smooth muscle cells via epidermal growth factor receptor/extracellular signal-regulated kinase/β-catenin signaling pathway

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 33, Issue 10, 2013, Pages 2397-2406

  Wong, Mei Mei ^a   Winkler, Bernhard ^a   Karamariti, Eirini ^a   Wang, Xiaocong ^a   Yu, Baoqi ^a   Simpson, Russell ^a   Chen, Ting ^a   Margariti, Andriani ^a   Xu, Qingbo ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

progenitor cells; sirolimus; stem cells; stents; vascular, smooth muscle

Indexed keywords

ALPHA SMOOTH MUSCLE ACTIN; BETA CATENIN; CALPONIN; CHEMOKINE RECEPTOR CCR2; CHEMOKINE RECEPTOR CCR3; CHEMOKINE RECEPTOR CCR9; CHEMOKINE RECEPTOR CX3CR1; CHEMOKINE RECEPTOR CXCR1; CHEMOKINE RECEPTOR CXCR2; CHEMOKINE RECEPTOR CXCR4; CHEMOKINE RECEPTOR CXCR4 ANTAGONIST; CHEMOKINE RECEPTOR CXCR5; CHEMOKINE RECEPTOR CXCR6; EPIDERMAL GROWTH FACTOR RECEPTOR; MAMMALIAN TARGET OF RAPAMYCIN; MITOGEN ACTIVATED PROTEIN KINASE 1; PLERIXAFOR; RAPAMYCIN; SHORT HAIRPIN RNA; SMALL INTERFERING RNA; STEM CELL ANTIGEN 1; STROMAL CELL DERIVED FACTOR 1;

ANIMAL CELL; ARTICLE; CELL DIFFERENTIATION; CELL MIGRATION; CELL POPULATION; CHEMOTAXIS; CONTROLLED STUDY; DRUG ELUTING STENT; EX VIVO STUDY; FLOW CYTOMETRY; GENE EXPRESSION; IN VITRO STUDY; INTIMA; NEOINTIMA; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; RECURRENT DISEASE; RESTENOSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; SMOOTH MUSCLE FIBER; STEM CELL; UPREGULATION; VASCULAR STEM CELL; WOUND HEALING;

PROGENITOR CELLS; SIROLIMUS; SMOOTH MUSCLE; STEM CELLS; STENTS; VASCULAR;

ACTIVE TRANSPORT, CELL NUCLEUS; ADULT STEM CELLS; ADVENTITIA; ANIMALS; ANTIGENS, LY; BETA CATENIN; BIOLOGICAL MARKERS; CALCIUM-BINDING PROTEINS; CELL PROLIFERATION; CELLS, CULTURED; CHEMOTAXIS; CONSTRICTION, PATHOLOGIC; ENZYME ACTIVATION; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; MEMBRANE PROTEINS; MICE; MICROFILAMENT PROTEINS; MUSCLE PROTEINS; MYOCYTES, SMOOTH MUSCLE; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTORS, CXCR4; RNA INTERFERENCE; SIGNAL TRANSDUCTION; SIROLIMUS; TIME FACTORS; TISSUE SCAFFOLDS; TRANSFECTION;

EID: 84885070926     PISSN: 10795642     EISSN: 15244636     Source Type: Journal    
DOI: 10.1161/ATVBAHA.113.301595     Document Type: Article

References (44)

1. Fattori R, Piva T. Drug-eluting stents in vascular intervention. Lancet. 2003;361:247-249
2. Costa MA, Simon DI. Molecular basis of restenosis and drug-eluting stents. Circulation. 2005;111:2257-2273
3. Banerjee S, Xu H, Fuh E, Nguyen KT, Garcia JA, Brilakis ES, Bhatt DL. Endothelial progenitor cell response to antiproliferative drug exposure. Atherosclerosis. 2012;225:91-98
4. Fukuda D, Sata M, Tanaka K, Nagai R. Potent inhibitory effect of sirolimus on circulating vascular progenitor cells. Circulation. 2005;111:926-931
5. Rotmans JI, Pattynama PM, Verhagen HJ, Hino I, Velema E, Pasterkamp G, Stroes ES. Sirolimus-eluting stents to abolish intimal hyperplasia and improve flow in porcine arteriovenous grafts: A 4-week follow-up study. Circulation. 2005;111:1537-1542
6. Marx SO, Jayaraman T, Go LO, Marks AR. Rapamycin-FKBP inhibits cell cycle regulators of proliferation in vascular smooth muscle cells. Circ Res. 1995;76:412-417
7. Poon M, Badimon JJ, Fuster V. Overcoming restenosis with sirolimus: From alphabet soup to clinical reality. Lancet. 2002;359:619-622
8. Morice MC, Serruys PW, Sousa JE, Fajadet J, Ban Hayashi E, Perin M, Colombo A, Schuler G, Barragan P, Guagliumi G, Molnar F, Falotico R. A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. N Engl J Med. 2002;346:1773-1780
9. Moses JW, Leon MB, Popma JJ, Fitzgerald PJ, Holmes DR, O'Shaughnessy C, Caputo RP, Kereiakes DJ, Williams DO, Teirstein PS, Jaeger JL, Kuntz RE. Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N Engl J Med. 2003;349:1315-1323
10. Schofer J, Schluter M, Gershlick AH, Wijns W, Garcia E, Schampaert E, Breithardt G. Sirolimus-eluting stents for treatment of patients with long atherosclerotic lesions in small coronary arteries: Double-blind, randomised controlled trial (E-SIRIUS). Lancet. 2003;362:1093-1099
11. Hu Y, Zhang Z, Torsney E, Afzal AR, Davison F, Metzler B, Xu Q. Abundant progenitor cells in the adventitia contribute to atherosclerosis of vein grafts in ApoE-deficient mice. J Clin Invest. 2004;113:1258-1265
12. Zengin E, Chalajour F, Gehling UM, Ito WD, Treede H, Lauke H, Weil J, Reichenspurner H, Kilic N, Ergün S. Vascular wall resident progenitor cells: A source for postnatal vasculogenesis. Development. 2006;133:1543-1551
13. Tang Z, Wang A, Yuan F, Yan Z, Liu B, Chu JS, Helms JA, Li S. Differentiation of multipotent vascular stem cells contributes to vascular diseases. Nat Commun. 2012;3:875
14. Campagnolo P, Cesselli D, Al Haj Zen A, Beltrami AP, Kränkel N, Katare R, Angelini G, Emanueli C, Madeddu P. Human adult vena saphena contains perivascular progenitor cells endowed with clonogenic and proangiogenic potential. Circulation. 2010;121:1735-1745
15. Passman JN, Dong XR, Wu SP, Maguire CT, Hogan KA, Bautch VL, Majesky MW. A sonic hedgehog signaling domain in the arterial adventitia supports resident Sca1+ smooth muscle progenitor cells. Proc Natl Acad Sci U S A. 2008;105:9349-9354
16. Tsai TN, Kirton JP, Campagnolo P, Zhang L, Xiao Q, Zhang Z, Wang W, Hu Y, Xu Q. Contribution of stem cells to neointimal formation of decellularized vessel grafts in a novel mouse model. Am J Pathol. 2012;181:362-373
17. Dietrich H, Hu Y, Zou Y, Dirnhofer S, Kleindienst R, Wick G, Xu Q. Mouse model of transplant arteriosclerosis: Role of intercellular adhesion molecule-1. Arterioscler Thromb Vasc Biol. 2000;20:343-352
18. Hu Y, Xu Q. Adventitial biology: Differentiation and function. Arterioscler Thromb Vasc Biol. 2011;31:1523-1529
19. Ergün S, Tilki D, Klein D. Vascular wall as a reservoir for different types of stem and progenitor cells. Antioxid Redox Signal. 2011;15:981-995
20. DeVries ME, Ran L, Kelvin DJ. On the edge: The physiological and pathophysiological role of chemokines during inflammatory and immunological responses. Semin Immunol. 1999;11:95-104
21. Cho C, Miller RJ. Chemokine receptors and neural function. J Neurovirol. 2002;8:573-584
22. Kiefer F, Siekmann AF. The role of chemokines and their receptors in angiogenesis. Cell Mol Life Sci. 2011;68:2811-2830
23. Margariti A, Winkler B, Karamariti E, Zampetaki A, Tsai TN, Baban D, Ragoussis J, Huang Y, Han JD, Zeng L, Hu Y, Xu Q. Direct reprogramming of fibroblasts into endothelial cells capable of angiogenesis and reendothelialization in tissue-engineered vessels. Proc Natl Acad Sci U S A. 2012;109:13793-13798
24. Chaturvedi D, Gao X, Cohen MS, Taunton J, Patel TB. Rapamycin induces transactivation of the EGFR and increases cell survival. Oncogene. 2009;28:1187-1196
25. Singh AM, Reynolds D, Cliff T, Ohtsuka S, Mattheyses AL, Sun Y, Menendez L, Kulik M, Dalton S. Signaling network crosstalk in human pluripotent cells: A Smad2/3-regulated switch that controls the balance between self-renewal and differentiation. Cell Stem Cell. 2012;10:312-326
26. Kiel MJ, Yilmaz OH, Iwashita T, Yilmaz OH, Terhorst C, Morrison SJ. SLAM family receptors distinguish hematopoietic stem and progenitor cells and reveal endothelial niches for stem cells. Cell. 2005;121:1109-1121
27. da Silva Meirelles L, Chagastelles PC, Nardi NB. Mesenchymal stem cells reside in virtually all post-natal organs and tissues. J Cell Sci. 2006;119(Pt 11):2204-2213
28. Minasi MG, Riminucci M, De Angelis L, et al. The meso-Angioblast: A multipotent, self-renewing cell that originates from the dorsal aorta and differentiates into most mesodermal tissues. Development. 2002;129:2773-2783
29. Hegner B, Lange M, Kusch A, Essin K, Sezer O, Schulze-Lohoff E, Luft FC, Gollasch M, Dragun D. mTOR regulates vascular smooth muscle cell differentiation from human bone marrow-derived mesenchymal progenitors. Arterioscler Thromb Vasc Biol. 2009;29:232-238
30. Schober A, Knarren S, Lietz M, Lin EA, Weber C. Crucial role of stromal cell-derived factor-1alpha in neointima formation after vascular injury in apolipoprotein E-deficient mice. Circulation. 2003;108:2491-2497
31. Zernecke A, Schober A, Bot I, von Hundelshausen P, Liehn EA, Möpps B, Mericskay M, Gierschik P, Biessen EA, Weber C. SDF-1alpha/CXCR4 axis is instrumental in neointimal hyperplasia and recruitment of smooth muscle progenitor cells. Circ Res. 2005;96:784-791
32. Chamberlain G, Wright K, Rot A, Ashton B, Middleton J. Murine mesenchymal stem cells exhibit a restricted repertoire of functional chemokine receptors: Comparison with human. PLoS One. 2008;3:e2934
33. Rosu-Myles M, Khandaker M, Wu DM, Keeney M, Foley SR, Howson-Jan K, Yee IC, Fellows F, Kelvin D, Bhatia M. Characterization of chemokine receptors expressed in primitive blood cells during human hematopoietic ontogeny. Stem Cells. 2000;18:374-381
34. Han W, Lo HW. Landscape of EGFR signaling network in human cancers: Biology and therapeutic response in relation to receptor subcellular locations. Cancer Lett. 2012;318:124-134
35. Sanchez-Guerrero E, Jo SR, Chong BH, Khachigian LM. EGFR and the complexity of receptor crosstalk in the cardiovascular system. Curr Mol Med. 2013;13:3-12
36. White GE, Tan TC, John AE, Whatling C, McPheat WL, Greaves DR. Fractalkine has anti-Apoptotic and proliferative effects on human vascular smooth muscle cells via epidermal growth factor receptor signalling. Cardiovasc Res. 2010;85:825-835
37. Brembeck FH, Rosário M, Birchmeier W. Balancing cell adhesion and Wnt signaling, the key role of beta-catenin. Curr Opin Genet Dev. 2006;16:51-59
38. Shafer SL, Towler DA. Transcriptional regulation of SM22alpha by Wnt3a: Convergence with TGFbeta(1)/Smad signaling at a novel regulatory element. J Mol Cell Cardiol. 2009;46:621-635
39. Caraci F, Gili E, Calafiore M, Failla M, La Rosa C, Crimi N, Sortino MA, Nicoletti F, Copani A, Vancheri C. TGF-beta1 targets the GSK-3beta/betacatenin pathway via ERK activation in the transition of human lung fibroblasts into myofibroblasts. Pharmacol Res. 2008;57:274-282
40. Hagenmueller M, Malekar P, Fieger C, Weiss CS, Buss SJ, Wolf D, Katus HA, Hardt SE. Depletion of mammalian target of rapamycin (mTOR) via siRNA mediated knockdown leads to stabilization of beta-catenin and elicits distinct features of cardiomyocyte hypertrophy. FEBS Lett. 2010;584:74-80
41. Campagnolo P, Wong MM, Xu Q. Progenitor cells in arteriosclerosis: Good or bad guys? Antioxid Redox Signal. 2011;15:1013-1027
42. Asahara T, Murohara T, Sullivan A, Silver M, Van Der Zee R, Li T, Witzenbichler B, Schatteman G, Isner JM. Isolation of putative progenitor endothelial cells for angiogenesis. Science. 1997;275:964-967
43. Hamesch K, Subramanian P, Li X, Dembowsky K, Chevalier E, Weber C, Schober A. The CXCR4 antagonist POL5551 is equally effective as sirolimus in reducing neointima formation without impairing re-endothelialisation. Thromb Haemost. 2012;107:356-368
44. Ma X, Hibbert B, Dhaliwal B, Seibert T, Chen YX, Zhao X, O'Brien ER. Delayed re-endothelialization with rapamycin-coated stents is rescued by the addition of a glycogen synthase kinase-3beta inhibitor. Cardiovasc Res. 2010;86:338-345